Lynparza Offers Benefits for Early-Stage HER2- BRCA+

Options
Moderators
Moderators Member Posts: 25,912
edited June 2021 in Genetic Testing

Lynparza Offers Benefits for Early-Stage HER2-Negative Breast Cancer With BRCA1/2 Mutation
June 10, 2021

Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival. Read more...

Comments

Categories